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Objective: Tuberculosis (TB) is a leading cause of death in human immunodeficiency virus 
(HIV)-positive individuals. We sought to compare mortality rates in TB/HIV co-infected 
individuals globally and by country/territory.
Design: We conducted a cross-national systematic assessment.
Methods: TB mortality rates in HIV-positive and HIV-negative individuals were obtained from 
the World Health Organization (WHO) Stop TB department for 212 recognized countries/ter-
ritories in the years 2006–2008. Multivariate linear regression determined the impact of health 
care resource and economic variables on our outcome variable, and TB mortality rates.
Results: In 2008, an estimated 13 TB/HIV deaths occurred per 100,000 population globally 
with the African region having the highest death rate ([AFRH] $4% adult HIV-infection rate) 
at 86 per 100,000 individuals. The next highest rates were for the Eastern European Region 
(EEUR) and the Latin American Region (LAMR) at 4 and 3 respectively per 100,000 population. 
African countries’ HIV-positive TB mortality rates were 29.9 times higher than non-African 
countries (95% confidence interval [CI]: 16.8–53.4). Every US$100 of government per capita 
health expenditure was associated with a 33% (95% CI: 24%–42%) decrease in TB/HIV mortal-
ity rates. The multivariate model also accounted for calendar year and did not include highly 
active antiretroviral therapy (HAART) coverage.
Conclusions: Our results indicate that while the AFRH has the highest TB/HIV death rates, 
countries in EEUR and LAMR also have elevated mortality rates. Increasing health expenditure 
directed towards universal HAART access may reduce mortality from both diseases.
Keywords: tuberculosis, HIV , antiretroviral therapy, mortality
Introduction
Tuberculosis (TB) and human immunodeficiency virus (HIV) are two devastating 
global infectious diseases. TB is one of the deadliest diseases of the 20th century 
and continues to claim millions of lives.1–4 The global HIV epidemic also continues 
to claim many lives, despite the global scale-up of antiretroviral (ARV) therapy. 
In 2008, an estimated 33.4 million people worldwide were living with HIV , and 
2.7 million were newly infected. More than 25 million people worldwide have died 
from HIV since the epidemic began.5
Immune-suppressed HIV-positive individuals are more likely to become co-infected 
with TB,6 which is a leading cause of death in this population,7 especially among those 
who reside in Sub-Saharan Africa.8,9 The dual burden of TB and HIV infection increases 
the likelihood of dying compared with having either disease separately.10–14 Previous 
studies have examined the effect of TB on mortality in HIV-infected i  ndividuals within Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Dovepress
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specific cohorts. For example, a recent study of TB patients 
in Nigeria found that 15.5% of HIV-positive individuals 
on treatment died, compared with 3.1% of HIV-negative 
individuals.13 There remains a dearth of research on global 
TB mortality in HIV-positive individuals.
The purpose of this analysis was to investigate the global 
burden of TB incidence and mortality in people with HIV . 
Our objectives were to determine rates of TB mortality in 
HIV-positive individuals compared with HIV-negative indi-
viduals by World Health Organization (WHO) designated 
regions, and to assess the effect of health care resources 
and economic variables on reducing TB/HIV co-infection 
mortality.
Methods
Data sources
The estimated number of TB (all forms) deaths among 
HIV-positive and HIV-negative individuals, along with 
health care resources and economic data by country/
territory were gathered from our prospectively maintained 
Globally Accumulated health Indicator Archive (GAIA) of 
publicly accessible health statistics for the years 2006–2008. 
The last available data was from 2008. Source data on TB 
death rates and incidence per 100,000 general population and 
the proportion of HIV among TB incident cases originated 
from statistics produced by the WHO’s Stop TB department. 
The ‘Year’, ‘Region’, and ‘Percent of HIV-positive new 
pulmonary smear-positive cases cured’ were obtained from 
WHO’s Stop TB department. ‘Percent HAART coverage’ 
data were obtained from WHO’s Towards Universal Access 
2009 report.15 ‘GDP’ (gross domestic product) in current 
international dollars (PPP, purchasing power parities), and 
‘Percent of women and men who received HIV testing in 
the last 12 months and know their results’ were obtained 
from UNDATA.16 Data for ‘Number of AIDS deaths’ were 
taken from UNAIDS.5 ‘Per capita government expenditure 
on health at average exchange rate (US$)’ and ‘Personal 
expenditure on health as % of total expenditure on health’ 
(year 2006 only) were obtained from WHO’s World Health 
Statistics 2009 report.17 ‘Average exchange rate’ specifies the 
observed annual average rate at which a currency is traded in 
the banking system. All source data were publicly accessible 
through the Internet.
All 212 recognized countries and territories listed in 
the WHO annual TB reports were included and classified 
into regions based on WHO designation. Regional clas-
sification were as follows: AFR, African countries with a 
low   HIV-infection rate (where ‘low’ refers to a generalized 
infection rate ,4% in adults aged 15–49 years in 2004) 
(N = 20 in 2006–2008); AFRH, African countries with a high 
HIV-  infection rate (N = 26 in 2006–2008); CEUR, Central 
European region (N = 10 in 2006–2008); EEUR, Eastern 
European region (N = 16 in 2006–2008); EMR, Eastern 
Mediterranean region (N = 17 in 2006–2008); EME, estab-
lished market economies (N = 56 in 2006–2008); LAMR, 
Latin American region (N = 31 in 2006–2008); SEAR, South-
East Asia region (N = 11 in 2006–2008); and WPR,   Western 
Pacific region (N = 25 in 2006–2008). Mortality rates 
were available for all countries/territories for each year 
(2006–2008) and are presented per 100,000 people for each 
country/territory. Each country’s total population size was 
taken from WHO’s Stop TB department statistics. To assess 
the difference in magnitude of HIV-positive to HIV-negative 
TB deaths, a ratio of the TB death rate in HIV-positive over 
HIV-negative individuals was calculated using each country’s 
mortality rates. A regional and global estimate of mortality 
rates was calculated for each year.
TB/hiV mortality model
The WHO produces estimates of TB incidence prevalence 
and mortality that are published in their annual TB report 
entitled, ‘Global Tuberculosis Control: Surveillance, 
Planning, Financing’.1–3 The most up-to-date estimates were 
based on data collected in 2009. The model involves creating 
a time-series of country-specific HIV-positive TB incidence 
distributions. These distributions incorporate two distribu-
tions of case fatality rates (in notified and nonnotified cases) 
among those co-infected with TB/HIV . Using simulations, 
the incidence rate distributions were multiplied with the case 
fatality rate distributions. A more detailed description of the 
changes to the modeling process from previously published 
‘Global Tuberculosis Control’ reports can be found in an 
update to the 2009 report.18
Analyses
Pearson’s correlation coefficient was used to assess the 
linear relationship between TB death rates in HIV-positive 
individuals and all explanatory variables aside from year, 
region, and highly active antiretroviral therapy (HAART) 
coverage for the years 2006–2008 and for the year 2008 
only. All relationships were evaluated graphically, and 
proper transformations were applied to render them linear. 
HAART coverage had to be dichotomized. The magnitude 
and sign of the coefficient represented the strength and 
direction of the linear relationship. P-values were calculated 
to test whether the correlation coefficient was significantly Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
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different from 0. Each test was based on different N values 
based on available data for each variable. ‘GDP’ was deemed 
redundant and therefore excluded from multivariate analyses. 
‘Percent of women and men who received HIV testing in the 
last 12 months and know their results’ and ‘Percent of HIV-
positive new pulmonary smear-positive cases cured’ were 
also excluded since they were poorly populated.
Countries and territories were re-categorized into African 
(AFR and AFRH) and non-African (CEUR, EEUR, EMR, 
EME, LAMR, SEAR, and WPR) for bivariate and multi-
variate analyses. T-tests for the linear regression coefficients 
were used to assess regional, yearly, and HAART coverage 
differences in the TB/HIV mortality rates from 2006–2008, 
and similarly for region and HAART coverage in the year 
2008 only. Separate multivariate linear regression analyses 
were then carried out to examine the effect of these variables 
on TB/HIV co-infection mortality for year 2006–2008 data 
and year 2008 data only. A total of 122 countries/territories 
were included for the year 2006–2008 analyses for a total of 
346 observations.   Observations could have been from year 
2006, 2007, or 2008. A total of 114 countries/territories were 
included in the year 2008 analyses for a total of 114 observa-
tions. The primary outcome measure in multivariate analysis 
was HIV-positive TB mortality rate per 100,000 general 
population, which was natural log-scaled in order to nor-
malize the distribution. The normality of the outcome was 
assessed using QQ-plots and Kolmogorov–Smirnov tests, 
both suggesting that the normal assumption was reasonable.19 
To standardize the scale of each explanatory variable’s data, 
‘AIDS deaths’ data were converted to a rate (number of AIDS 
deaths over the HIV-positive population). Percent HAART 
coverage was calculated by dividing the number of persons 
receiving HAART treatment at the end of 2006, 2007, and 
2008 by the total estimated need for HAART in 2007.15 In 
the 3-year model, repeated measures were accounted for 
using unstructured correlation matrices in the GENMOD 
procedure.46 Health expenditure units were converted to the 
format ‘current $100 US per capita’. Model selection was 
achieved through minimization of the Akaike information 
criterion (AIC)20 and applying the additional constraint that 
all coefficient P-values be below 0.20.
Results
All 212 countries included in the analyses had a TB incidence 
rate, a value for the proportion of HIV among TB incident 
cases, and a TB/HIV mortality rate for years 2006–2008.
Table 1 is a global summary of all nine regions’ HIV-
associated average TB mortality and incidence rates per 
100,000 people and proportion of HIV among TB incident 
cases for the years 2006–2008 with low and high uncer-
tainty bounds. Of note, the AFR and AFRH had 13 and 86 
HIV-positive TB mortality rates in 2008, respectively. AFRH 
had a HIV-positive TB mortality rate 2.2 times greater than 
its HIV-negative TB mortality rate in the same year. AFRH 
TB/HIV mortality rates were approximately 717 times higher 
than EME in 2008. Figure 1 shows TB/HIV mortality rates 
by region in 2008.
Bivariate analyses of the relationship between the explan-
atory variables and TB death rates in HIV-positive individu-
als for the years 2006–2008 revealed that ‘AIDS death rate’ 
showed a positive linear relationship with TB/HIV mortality 
rates over the three years (Pearson’s correlation coefficient: 
0.350) while ‘Government health expenditure’, ‘GDP’, and 
‘Percentage of men and women who know HIV test results’ 
showed an overall negative linear relationship (Pearson’s 
correlation coefficient: -0.741, -0.384, and -0.172, respec-
tively). All explanatory variables were correlated to TB/HIV 
mortality rates overall (P , 0.05).
Table 2 shows the median and interquartile ranges for 
TB/HIV mortality rates by year and region. All regions’ 
mortality rates differed significantly from each other 
in each year from 2006 to 2008 (P , 0⋅001). In those 
years, African (AFR and AFRH countries) mortality rates 
were significantly different from non-African countries 
(P , 0.001). The overall median HIV mortality rates in 
each of those three years also differed significantly from 
each other (P = 0.002).
The unadjusted and adjusted multivariable regres-
sion analyses for 122 countries/territories for the years 
2006–2008 are reported in Table 3. In unadjusted analyses, 
region,   government health expenditure, proportion of per-
sonal health expenditure out of total health expenditure, 
AIDS death rate, and HAART coverage were signifi-
cantly associated with HIV-positive TB mortality rates 
(P , 0.001). Countries with HAART coverage ,15% 
were associated with a TB/HIV mortality rate 3.6 times 
higher than countries with .15% coverage (P = 0.0004). 
In adjusted analyses, region and government health 
expenditure were independently associated with TB/
HIV mortality rates (P , 0.05). Year was marginally 
independently associated with TB/HIV mortality rates 
(P , 0.2). Compared with elsewhere in the world, HIV-
positive TB mortality rates increased by 29.9 times in 
African countries (P , 0.0001). In 2008, HIV-positive 
TB mortality rates increased by 1% compared with 2006. 
A US$100 increase in government health expenditure per Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Figure 1 HIV-positive TB mortality rates by WHO-defined region, excluding African countries with high HIV-infection rate (AFRH), 2008. Africa-countries with low HIV-infection 
rate (AFr) (n = 20), Central European region (CEUr) (n = 10), Eastern European region (EEUr) (n = 16), Eastern Mediterranean region (EMr) (n = 17), established market 
economies (EME) (n = 56), Latin American region (LAMr) (n = 31), south-East Asia region (sEAr) (n = 11), and Western Pacific region (WPR) (N = 25). Total n = 212.
Abbreviations: hiV, human immunodeficiency virus; TB, tuberculosis; WHO, World Health Organization.
Table 2 A comparison between TB/hiV mortality rates by region and year
Year 2006 2007 2008 All years
Region Nb Median  
(interquartile  
range)c
Nb Median  
(interquartile  
range)c
Nb Median  
(interquartile 
range)c
Nb Median 
(interquartile  
range)c
African region (AFr) 20 7.89 (1.25–15.90) 20 6.84 (0.52–16.37) 20 8.02 (1.97–18.25) 60 7.85 (0.70–16.51)
African regiona  
(AFrh)
26 61.81 (32.30–124.59) 26 55.58 (31.13–117.34) 26 52.60 (29.70–104.59) 78 55.88 (31.13–117.34)
Central European  
region (CEUr)
10 0.00 (0.00–0.12) 10 0.00 (0.00–0.12) 10 0.00 (0.00–0.03) 30 0.00 (0.00–0.09)
Eastern European  
region (EEUr)
16 0.39 (0.24–1.25) 16 0.57 (0.39–1.86) 16 0.48 (0.27–2.24) 48 0.49 (0.29–1.88)
Eastern  
Mediterranean  
region (EMr)
17 0.05 (0.00–0.23) 17 0.07 (0.00–0.21) 17 0.05 (0.00–0.19) 51 0.05 (0.00–0.23)
Established market 
economies (EME)
56 0.05 (0.00–0.12) 56 0.03 (0.00–0.11) 56 0.03 (0.00–0.10) 168 0.03 (0.00–0.12)
Latin American  
region (LAMr)
31 1.13 (0.20–2.46) 31 1.06 (0.003–2.82) 31 1.15 (0.18–2.92) 93 1.13 (0.19–2.66)
south-East Asia  
region (sEAr)
11 0.05 (0.00–1.38) 11 0.06 (0.00–1.61) 11 1.36 (0.04–3.92) 33 0.08 (0.04–1.61)
Western Pacific  
region (WPr)
25 0.00 (0.00–0.25) 25 0.00 (0.00–0.15) 25 0.00 (0.00–0.53) 75 0.00 (0.00–0.27)
African (AFr + AFrh) 46 28.87 (8.33–64.74) 46 27.88 (6.78–64.68) 46 25.17 (8.03–64.85) 138 27.45 (8.01–64.74)
non-African 166 0.10 (0.00–0.76) 166 0.08 (0.00–0.84) 166 0.08 (0.00–1.03) 498 0.09 (0.00–0.85)
TOTAL (all regions) 212 0.20 (0.004–3.33) 212 0.15 (0.00–3.14) 212 0.18 (0.00–3.43) 636 0.19 (0.00–3.25)
Notes: aAfrican countries with a generalized hiV-infection rate ($4% in adults aged 15–49 in 2004); bn represents the number of countries from each region with TB/hiV 
mortality rates; cPer 100,000 general population.
Abbreviations: HIV, human immunodeficiency virus; TB, tuberculosis.
capita was   associated with a 0.67 (95% confidence interval 
[CI]: 0.58, 0.76) unit increase TB/HIV mortality rates), 
in other words, every US$100 dollars spent on health 
expenditure per capita was associated with 33% reduction 
in mortality rates (P , 0.0001).
The unadjusted and adjusted multivariable regression 
analyses for 114 countries/territories in 2008 are reported in 
Table 4. In unadjusted analyses, region, government health 
expenditure, the proportion of personal health expenditure 
out of total health expenditure and the AIDS death rate were Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Dovepress
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Table 3 Multivariate analyses of factors associated with hiV-positive TB mortality rate (year 2006–2008), n = 122 countries/territories 
(n = 115 countries in 2006, n = 117 countries in 2007, and n = 114 countries in 2008; total of n = 134 observations)
Variable HIV-positive TB mortality ratea
Unadjusted relative risk Adjusted relative risk
Estimate (95% CI) P-value Estimate (95% CI) P-value
region non-African 1 (–) ,0.0001 1 (–) ,0.0001
African 76.17 (44.99–128.98) 29.93 (16.76–53.44)
Year 2006 1 (–) 0.1908 1 (–) 0.0919
2007 0.59 (0.27–1.3) 0.67 (0.38–1.18)
2008 0.91 (0.41–2.03) 1.01 (0.57–1.79)
government health expenditure 
at average exchange rate  
(logarithm of, Us$100 per capita)
0.45 (0.39–0.51) ,0.0001 0.67 (0.58–0.76) ,0.0001
Personal health expenditure  
as a percentage of total  
health expenditure (%)
1.05 (1.03–1.07) ,0.0001 Not included in final model
AiDs death rate (logarithm of) 1.34 (1.14–1.57) 0.0003 Not included in final model
hAArT coverage (%) ,15%  
$15%
3.6 (1.76–7.35)  
1 (–)
0.0004 Not included in final model
Note: anatural log-scaled hiV-positive TB mortality rate.
Abbreviations: AIDS, acquired immunodeficiency syndrome; CI, confidence interval; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; 
TB, tuberculosis.
Table 4 Multivariate analyses of factors associated with 2008 hiV-positive TB mortality rate, n = 114 countries/territories
Variable HIV-positive TB mortality ratea
Unadjusted relative risk Adjusted relative risk
Estimate (95% CI) P-value Estimate (95% CI) P-value
region non-African 1 (–) ,0.0001 1 (–) ,0.0001
African 68.17 (30.26–153.57) 28.88 (11.71–71.21)
government health expenditure  
at average exchange rate (logarithm  
of, Us$100 per capita)
0.44 (0.36–0.53) ,0.0001 0.73 (0.56–0.95) 0.0178
Personal health expenditure as a percentage  
of total health expenditure (%)
1.06 (1.03, 1.08) ,0.0001 1.02 (1.00–1.05) 0.1168
AiDs death rate (logarithm of) 3.72 (2.07–6.69) ,0.0001 Not included in final model
hAArT coverage (%) ,15%  
$15%
1.47 (0.5–4.3)  
1 (–)
0.9548 Not included in final model
Note: anatural log-scaled hiV-positive TB mortality rate.
Abbreviations: AIDS, acquired immunodeficiency syndrome; CI, confidence interval; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; 
TB, tuberculosis.
significantly associated with HIV-positive TB mortality rates 
(P , 0.0001).
In adjusted analyses, region and government health expen-
diture were independently associated with TB/HIV mortality 
rates (P , 0.05). The proportion of personal health expenditure 
out of total health expenditure was marginally independently 
associated with TB/HIV mortality rates (P , 0.2). Compared 
with elsewhere in the world, HIV-positive TB mortality rates 
were higher by 28.9 times in African countries (P , 0⋅0001). 
Increasing the proportion of personal health expenditure out 
of total health expenditure was associated with a 2% increase 
in TB/HIV mortality rates (P = 0.1168). A one hundred   dollar 
increase in health expenditure per capita was associated 
with a 0.73 (95% CI: 0.56, 0.95) unit increase in TB/HIV 
  mortality rates, meaning, every one hundred US dollars spent 
on   government health expenditure per capita was associated 
with a 27% reduction in mortality rates (P , 0.05).
Discussion
Our results indicate that in 2008, the highest TB mortality 
rates among HIV-positive individuals were in Africa, 
followed by the EEUR, LAMR, and SEAR. Multivariate 
analyses confirmed that Africa had significantly higher TB/
HIV mortality rates than non-African regions. Our adjusted 
multivariate analysis for the year 2008 revealed an asso-
ciation between government health expenditure and lower Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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TB/HIV mortality rates. Personal health expenditure was 
associated with higher TB/HIV mortality rates.
Regions known to have a high HIV prevalence were iden-
tified to have proportionally higher HIV-positive TB death 
rates in our results.5 High TB incidence and mortality among 
HIV-positive individuals in the African region lends support 
to our findings that African countries bear the highest burden 
from both diseases.1,8,9 However, non-African regions contain-
ing countries/territories known to have a high-burden of TB 
also had elevated TB/HIV mortality rates, suggesting that this 
burden is not limited to Africa.1 The ratio (.1) of HIV-positive 
to HIV-negative TB mortality rates in the AFRH confirms the 
greater mortality risk in TB/HIV co-infected individuals.
Our study revealed that increasing per capita government 
health expenditure might lower TB/HIV mortality rates. 
Since developing regions in the world bear the highest TB/
HIV burden, these regions would benefit the most from an 
increase in financial resources. There is a critical need for 
increased collaboration between HIV and TB management 
due to the overlapping impact of the diseases. For example, 
provider-initiated HIV-testing for TB patients in developing 
regions is poorly implemented,21 even though this has been 
regarded as a key entry point into ARV therapy for undiag-
nosed individuals.22–25 Furthermore, the “Three I’s” principle 
of Isoniazid preventative therapy, Intensified TB case find-
ing, and Infection control is widely viewed as an effective 
TB management strategy in HIV-infected individuals.26–30 
However, a lack of formal resources has compromised these 
initiatives, including basic laboratory services that detect 
HIV-associated TB, particularly smear-negative dissemi-
nated and drug resistant forms.31,32 Before strategy becomes 
common practice, developing infrastructure and relevant 
operational details to supplement policy can ensure service 
delivery to individuals in need.33
In contrast, our findings also showed that increasing 
the proportion of personal health expenditure out of total 
health expenditure might increase TB/HIV mortality rates. 
Research on treatment-seeking behavior in the African setting 
revealed a lower proportion of patients actively seeking 
health care prior to requiring mandatory hospitalization when 
out-of-pocket payments were required.34 Other studies have 
shown that out-of-pocket payments increase the likelihood 
of patients self-medicating or delaying treatment until their 
condition worsens.35,36 This evidence suggests that countries 
with the highest TB/HIV burden may need to increase public 
health care expenditure.
TB/HIV health care services have been favored for 
expansion,33 such as provider-initiated HIV testing and 
elements of the “Three I’s” program which have been 
evaluated for cost-effectiveness.37,38 Recently, increasing 
HAART coverage combined with early ARV treatment has 
been championed as a strategy to decrease TB incidence.39 
Yet, national budgets in high TB-burdened countries have 
allocated limited funds to support TB/HIV collaborations.3 
When examining the resources dedicated to each disease 
separately, HIV/AIDS health expenditure has expanded 
dramatically compared with other related sectors.40 In stark 
contrast, financial resources dedicated to TB have been 
a fraction of that,3,40 allocated mostly to DOTS (directly 
observed treatment, short-course), the recommended strat-
egy for TB control.41 Yet, DOTS has been questioned as an 
effective method for controlling the disease.25,42 HAART 
coverage was significantly associated with lower TB/HIV 
mortality rates in bivariate analysis (2006–2008), but was 
not independently associated with these same rates in our 
multivariate model. This suggests that HAART coverage 
is dependent on public health expenditure. Given that HIV/
AIDS and TB are both devastating infectious diseases, the 
striking disparity in TB to HIV funding not only calls for 
greater financial resources dedicated to combat TB, but 
also, more specifically, investment in programs such as 
widespread HAART distribution that may enhance treat-
ment for both diseases.
There are limitations to consider with this analysis. Since 
our primary source of data was from WHO, our analyses 
relied on estimates based on their calculation methodology. 
Their source data were based on a dearth of documented mor-
tality cases reported to them from each country/territory.1–3,18 
In a cohort study and literature review assessing the burden 
of TB, similar limitations may have led to an underestima-
tion of TB deaths among the HIV-positive population.4,43 In 
addition, many countries that do report vital statistics do 
not subcategorize an HIV death as being TB-associated. 
  Moreover, TB incidence, a mortality model input, is not 
directly measureable and instead relies on obtaining expert 
opinion. No country has ever completed a national survey 
of TB incidence nor established criteria for verifying the 
reliability of a country’s routine TB surveillance system. 
  However, continued improvements have been made to WHO 
data collection methodologies from years past, such that the 
rise of HIV-testing in TB patients has contributed to a substan-
tial increase in the number of reported TB deaths associated 
with HIV .3,44,45 Additionally, not all countries/  territories from 
a region may share the same mortality burden, since those 
with a high rate of TB/HIV mortality would have skewed 
regional average mortality rates.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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A lack of comprehensive and complete country data on 
health care resources limited our bivariate and multivariate 
analyses. Since our sample size was restricted to countries 
with data available for every explanatory variable, our findings 
may not be applicable to all regions. Additionally, we were 
limited by a lack of recent statistics. For example, ARV treat-
ment coverage for year 2008 was calculated using statistics 
from 2007 while health expenditure for 2008 was extrapolated 
from 2006 data. These findings underscore the need for more 
comprehensive and updated global health statistics.
Our findings on the global burden of TB mortality in HIV-
positive individuals call for additional investigation in this 
area. This study is unique because it relates the worldwide 
burden of HIV-related TB mortality to the latest publicly 
available health indicator data. We found incomplete national 
health indicator data which limits thorough and ideal global 
analyses. Nevertheless, our study encourages further discus-
sion on the issue of reducing these diseases’ death toll, espe-
cially in developing nations. Finally, it is clear that there is an 
urgent need for increased public funding toward TB health 
care services that have long-term effectiveness in high HIV-
prevalence settings. This funding should be directed towards 
developing widespread HAART distribution programs.
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